Complication Rates After Bone Morphogenetic Protein (BMP) Use in Orthopaedic Surgery in Children: A Concise Multicenter Retrospective Cohort Study.
BACKGROUND
The use of bone morphogenetic protein (BMP) has been associated with a number of complications in adult patients. However, this association is less established in children. The aim of this study was to evaluate the safety of BMP use in children by determining the complication rates after BMP use at multiple institutions.


METHODS
In a retrospective study (2000 to 2013), the medical records of all patients who received BMP at any of the 5 institutions were reviewed. Demographic information, preoperative data, and postoperative follow-up data were collected on those patients who were under the age of 18 at the time of surgery.


RESULTS
A total of 312 pediatric patients underwent surgery with BMP application during the study period. The surgical procedures consisted of 228 spinal fusions, 39 pars repairs, 33 nonunion repair, and 12 other various procedures. Overall 21% (65/312) of patients who had BMP utilized had a complication. Fifty-five percent (36/65) of patients with a complication required a revision surgery. The average follow-up was 27 months (range, 3 to 96 mo); 80% of patients had a follow-up period of >12 months. The average age at the time of surgery was 13 years (range, 1 to 17 y). Males and females were almost equally represented in the study: 143 males (46%) and 168 females (54%). Of the patients who received BMP, 9% had minor complications and 13% had major complications. Wound dehiscence without infection was the most common minor complication and occurred in 59% (16/27) of patients with minor complications. Infection and implant failures were the most frequent major complications, occurring in 38% (15/39) and 33% (13/39) of patients with major complications, respectively. Five of 312 (2%) patients had neurological injury, 3 of which were only temporary.


CONCLUSIONS
This multicenter study demonstrates a relatively high rate of complications after the use of BMP in children. However, further study is needed to attribute the complications directly to the use of BMP.


METHODS
Level IV.
*Division of Orthopaedic Surgery, Children's Hospital Colorado, Aurora, CO †Division of Orthopaedic Surgery, Cincinnati Children's Hospital, Cincinnati ‡Division of Orthopaedic Surgery, Cleveland Clinic Foundation, Cleveland, OH §Division of Orthopaedic Surgery, Children's Hospital of Philadelphia ∥Division of Orthopaedic Surgery, Shriners Hospital for Children, Philadelphia ¶Division of Orthopaedic Surgery, Penn State Hersey Medical Center, Hershey, PA.
Sumeet
S
Garg
James J
JJ
McCarthy
Ryan
R
Goodwin
Joel
J
Kolmodin
Wudbhav N
WN
Sankar
Corinna
C
Franklin
Douglas
D
Armstrong
David
D
Fryzel
Susan
S
Hassenbein
Cara
C
Meder
D000293:Adolescent; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D056687:Off-Label Use; D019637:Orthopedic Procedures / Q000706:statistics & numerical data*; D011183:Postoperative Complications / Q000209:etiology*; D011184:Postoperative Period; D012086:Reoperation / Q000706:statistics & numerical data; D012189:Retrospective Studies
D019485:Bone Morphogenetic Proteins